Verhoeven C H, Krebbers S F, Wagenaars G N, Booy C J, Groothuis G M, Olinga P, Vos R M
Department of Toxicology and Drug Disposition, University Centre for Pharmacy, Oss, The Netherlands.
Drug Metab Dispos. 1998 Nov;26(11):1102-12.
The metabolism of Org 30659 [(17alpha)-17-hydroxy-11-methylene-19-norpregna-4, 15-dien-20-yn-3-one], a new potent progestagen currently under clinical development by NV Organon for use in oral contraceptive and hormone replacement therapy, was studied in vivo after oral administration to rats and monkeys and in vitro using rat, rabbit, monkey, and human liver microsomes and rat and human hepatocytes. After oral administration of [7-3H]Org 30659 to rats and monkeys, Org 30659 was extensively metabolized in both species. Fecal excretion appeared to be the main route of elimination. In rats, opening of the A-ring, resulting in a 2-OH,4-carboxylic acid, 5alpha-H metabolite of Org 30659, was the major metabolic route in vivo. Other metabolic routes involved the introduction of an OH group at C15beta, followed by a shift of the Delta15-double bond to a 16/17-double bond with subsequent removal of the OH group at C17 and reduction of the 3-keto,Delta4 moiety followed by sulfate conjugation of the 3-OH substituent. These metabolic routes observed in vivo were also major routes in incubations with rat hepatocytes. In rat liver microsomes, Org 30659 was metabolized by reduction of the 3-keto,Delta4 moiety. Rat hepatocyte incubations with Org 30659 were more representative of the in vivo metabolism of Org 30659, compared with rat microsomal incubations. Both in vitro and in vivo, the majority of the metabolites were 3alpha-OH,4,5alpha-dihydro derivatives. In monkeys, Org 30659 was mainly metabolized at the C3- and C17-positions in vivo. The 3-keto moiety was reduced to both 3beta-OH and 3alpha-OH substituents. In addition to phase I metabolites, glucuronic acid conjugates were observed in vivo. In monkey liver microsomes, the 6beta-OH metabolite of Org 30659 was the major metabolite present. Similar to the monkey liver microsomes, rabbit and human liver microsomes converted Org 30659 to the 6beta-OH metabolite. This metabolite was also the major metabolite in incubations with human hepatocytes.
奥格30659[(17α)-17-羟基-11-亚甲基-19-去甲孕甾-4,15-二烯-20-炔-3-酮]是欧加农公司目前正在临床开发用于口服避孕药和激素替代疗法的一种新型强效孕激素。给大鼠和猴子口服给药后,在体内对其代谢情况进行了研究,并利用大鼠、兔子、猴子和人的肝微粒体以及大鼠和人的肝细胞在体外进行了研究。给大鼠和猴子口服[7-³H]奥格30659后,奥格30659在这两个物种中均被广泛代谢。粪便排泄似乎是主要的消除途径。在大鼠体内,A环开环,生成奥格30659的2-羟基、4-羧酸、5α-H代谢物,这是体内主要的代谢途径。其他代谢途径包括在C15β位引入一个羟基,随后Δ¹⁵-双键转移至16/17-双键,接着去除C17位的羟基,3-酮、Δ⁴部分还原,随后3-羟基取代基硫酸化结合。在体内观察到的这些代谢途径在与大鼠肝细胞孵育时也是主要途径。在大鼠肝微粒体中,奥格30659通过3-酮、Δ⁴部分的还原进行代谢。与大鼠微粒体孵育相比,用奥格30659孵育大鼠肝细胞更能代表奥格30659的体内代谢情况。在体外和体内,大多数代谢物都是3α-羟基、4,5α-二氢衍生物。在猴子体内,奥格30659主要在C3和C17位代谢。3-酮部分还原为3β-羟基和3α-羟基取代基。除I相代谢物外,在体内还观察到葡糖醛酸结合物。在猴肝微粒体中,奥格30659的6β-羟基代谢物是主要存在的代谢物。与猴肝微粒体类似,兔和人的肝微粒体将奥格30659转化为6β-羟基代谢物。该代谢物也是与人肝细胞孵育时的主要代谢物。